Presymptomatic Versus Late Cerliponase Alfa Therapy in CLN2 Disease: Sibling Case Report
Open Access
- 1 January 2026
- journal article
- Published by FapUNIFESP (SciELO) in Journal of Inborn Errors of Metabolism and Screening
- Vol. 14
Abstract
Neuronal ceroid lipofuscinosis type 2 (CLN2) is a rapidly progressive neurodegenerative disorder caused by TPP1 deficiency. Intracerebroventricular cerliponase alfa slows motor-language decline, although outcomes vary with disease stage at treatment initiation. Intrafamilial comparisons remain scarce, particularly in Latin America. We report two Colombian siblings carrying identical compound heterozygous TPP1 variants (c.622C>T [p.Arg208*] and c.887-10A>G) with markedly reduced enzyme activity. The older brother began enzyme replacement therapy (ERT) at age 11 with advanced neurologic impairment; whereas his sister started presymptomatically at age 3 following cascade testing. Clinical scales, neuroimaging, and cerebrospinal fluid neurofilament light (CSF NfL) levels were analyzed during 5-6 years of treatment. Before diagnosis, the brother developed language regression, ataxia, epilepsy, and visual decline. After ERT initiation, no further major motor milestone loss ocurred, seizures remained controlled, and severe disability persisted; CSF NfL decreased from 1,334 to 504 pg/mL during maintenance. His sister remained neurologically intact at age 9, with preserved motor-language function, normal MRI, and maintenance-phase CSF NfL levels of 359-531 pg/mL. These divergent intrafamilial trajectories support early TPP1 testing and prompt cascade screening in at-risk siblings, although longer follow-up is required to establish the durability of presymptomatic benefit.This publication has 25 references indexed in Scilit:
- Enzyme Replacement Therapy in CLN2-Associated RetinopathyKlinische Monatsblätter für Augenheilkunde, 2025
- Safety and efficacy of cerliponase alfa in children with neuronal ceroid lipofuscinosis type 2 (CLN2 disease): an open-label extension studyThe Lancet Neurology, 2023
- Language Delay in Patients with CLN2 Disease: Could It Support Earlier Diagnosis?Neuropediatrics, 2023
- Neurofilament light chain and glial fibrillary acidic protein levels in metachromatic leukodystrophyBrain, 2021
- Neurofilament light is a treatment‐responsive biomarker in CLN2 diseaseAnnals of Clinical and Translational Neurology, 2019
- Disease characteristics and progression in patients with late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2) disease: an observational cohort studyThe Lancet Child & Adolescent Health, 2018
- Study of Intraventricular Cerliponase Alfa for CLN2 DiseaseNew England Journal of Medicine, 2018
- Late Infantile Neuronal Ceroid Lipofuscinosis: A New Mutation in ArabsPediatric Neurology, 2009
- 1 Neuronal ceroid lipofuscinoses: Classification and diagnosis2001
- Structural Organization and Sequence ofCLN2,the Defective Gene in Classical Late Infantile Neuronal Ceroid LipofuscinosisGenomics, 1998